Navigation Links
Rhythm Names Keith M. Gottesdiener Chief Executive Officer
Date:11/9/2011

BOSTON, Nov. 9, 2011 /PRNewswire-USNewswire/ -- Rhythm, a biotechnology company developing peptide therapeutics for metabolic diseases, announced today the appointment of Keith M. Gottesdiener, MD, as Chief Executive Officer. Dr. Gottesdiener joins Rhythm from Merck & Co., Inc., where he served as Vice President and Late-Stage Therapeutic Group Leader, with responsibility for pivotal trials of Merck's products in all therapeutic areas, and previously as head of early-stage clinical development programs.

"The Rhythm clinical candidates are peptides with some important advantages over small molecules for targeting complex pathways that regulate body weight and gastrointestinal function," said Dr. Gottesdiener. "I am excited to join the Rhythm team to develop this pipeline of peptide therapeutics that have real potential to become breakthrough drugs for obesity, diabetes, and GI metabolic disorders."

Over a 16-year career at Merck, Dr. Gottesdiener was responsible for more than 40 major clinical programs and products, including the approval of Gardasil™ (HPV vaccine) and the more recent FDA approval of Victrelis™ (HCV protease inhibitor). Dr. Gottesdiener received an A.B. from Harvard College and an M.D. from the University of Pennsylvania, and he completed his residency and fellowship at the combined Brigham and Women's Hospital-Beth Israel Medical Center-Dana Farber Cancer Institute Children's Hospital programs.

"Keith's experience and accomplishments developing innovative, best-in-class drugs—including the diabetes blockbuster, Januvia™—are exceptional," said Bart Henderson, President and co-founder of Rhythm. "He comes to Rhythm at an ideal time, as we advance clinical development of RM-131 for the treatment of diabetic gastroparesis and RM-493 for obesity and diabetes."

"Keith's deep understanding of the clinical development process will greatly enhance Rhythm's novel approach to molecular mechanisms of body weight regulation," said Lou Tartaglia, Ph.D., Rhythm's Chief Scientific Officer and a Partner at Third Rock Ventures. "We are very excited to have attracted such world-class talent to join us in building a great company in the metabolic field."

About Rhythm (www.rhythmtx.com)

Rhythm is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm investors include MPM Capital, New Enterprise Associates, and Third Rock Ventures. The company is based in Boston, Massachusetts.

Contact:
Bart Henderson
President
(857) 264-4281
bhenderson@rhythmtx.com


'/>"/>
SOURCE Rhythm
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Differing structures underlie differing brain rhythms in healthy and ill
2. Dangerous arrhythmia analyzed in a heartbeat
3. Rhythms RM-131 Restores GI Function as a Potent Ghrelin Prokinetic
4. Biosense Webster Reinforces its Leadership Position in the Electrophysiology Market at Heart Rhythm 2010
5. Boston Scientific to Donate Cardiac Rhythm Management Devices to Heartbeat International for Implantation in Needy Patients
6. Boston Scientific Announces Company Schedule for Heart Rhythm Society Scientific Sessions
7. Guam rhino beetles got rhythm
8. FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c
9. FierceBiotech Names Pearl Therapeutics a 2011 Fierce 15 Biotech
10. OXIS International Names David Saloff as Chief Executive Officer
11. Numira Biosciences Names New Board Member
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... , Oct. 10, 2017 International research firm Parks Associates ... will speak at the TMA 2017 Annual Meeting , October 11 ... in the residential home security market and how smart safety and security ... Parks Associates: ... "The residential security ...
(Date:10/10/2017)... PITTSBURGH, PA (PRWEB) , ... October 10, 2017 ... ... this year’s recipients of 13 prestigious awards honoring scientists who ... be presented in a scheduled symposium during Pittcon 2018, the world’s leading conference ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board meeting in ... professor in Harvard University’s Departments of Physics and Astronomy, has been selected for membership ... the winning team for the 2015 Breakthrough Prize in Fundamental physics for the discovery ...
(Date:10/7/2017)... (PRWEB) , ... October 06, ... ... years’ experience providing advanced instruments and applications consulting for microscopy and surface ... expertise in application consulting, Nanoscience Analytical offers a broad range of contract ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
(Date:3/27/2017)... 2017  Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting.  This recognition ...
Breaking Biology News(10 mins):